In vitro maturation в рамках сохранения фертильности при онкологической патологии

Доброхотова Ю.Э., Лапина И.А., Малахова А.А., Чирвон Т.Г., Таранов В.В., Сорокин Ю.А., Гомзикова В.М., Затеева А.А., Твердикова М.В., Кайкова О.В. In vitro maturation в рамках сохранения фертильности при онкологической патологии. Гинекология. 2023;25(3):314–319. DOI: 10.26442/20795696.2023.3.202323

© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.

________________________________________________

Dobrokhotova YuE, Lapina IA, Malakhova AA, Chirvon TG, Taranov VV, Sorokin YuA, Gomzikova VM, Zateeva AA, Tverdikova MV, Kaykova OV. In vitro maturation for fertility preservation in patients with cancer: A review. Gynecology. 2023;25(3):314–319. DOI: 10.26442/20795696.2023.3.202323

Читать PDF

Аннотация

Согласно статистике Всемирной организации здравоохранения ежегодно увеличивается число пациентов репродуктивного возраста, которые сталкиваются с онкологическими заболеваниями. В связи с этим улучшение качества жизни данной категории больных является одной из приоритетных задач медицинского сообщества. Известно, что более 30% женщин, столкнувшихся с онкологией, на момент заболевания еще не реализовали свою репродуктивную функцию. Поэтому одним из ведущих направлений в медицине является разработка и усовершенствование методов сохранения репродуктивной функции. Созревание ооцитов in vitro – одна из перспективных методик, реализуемых в рамках онкофертильности, которая используется в качестве альтернативы традиционных циклов стимуляции овуляции, с последующим получением зрелых ооцитов. Цель данного обзора состоит в изучении процедуры in vitro maturation, анализе данных мировой литературы относительно ее эффективности и безопасности при использовании данной методики в программах по сохранению репродуктивного материала у пациенток с онкологическими заболеваниями.

Ключевые слова: онкофертильность, гонадотоксичность, созревание in vitro, незрелый ооцит

________________________________________________

According to the World Health Organization, the number of patients of reproductive age with cancer steadily increases. Therefore, improving their quality of life is one of the priority tasks of the medical community. It is known that more than 30% of women with cancer at the time of diagnosis have not yet given birth. Therefore, one of the relevant issues is developing and improving methods for preserving reproductive function. In vitro oocyte maturation is a promising technique of oncofertility, which is used as an alternative to traditional cycles of ovulation stimulation followed by the production of mature oocytes. This review aims to study the in vitro maturation procedure and analyze the literature data regarding its effectiveness and safety when used as a part of programs for preserving reproductive material in patients with cancer.

Keywords: oncofertility, gonadotoxicity, in vitro maturation, immature oocyte

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Назаренко Т.А., Ашрафян Л.А., Джанашвили Л.Г., Мартиросян Я.О. Сохранение репродуктивного материала у онкологических больных как медико-социальная и организационная проблема. Онкология. Журнал им. П.А. Герцена. 2020;9(1):60-5 [Nazarenko TA, Ashrafian LA, Dzhanashvili LG, Martirosyan YO. Retention of reproductive material in cancer patients as a sociomedical and organizational problem. P.A. Herzen Journal of Oncology. 2020;9(1):60-5 (in Russian)].
2. Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril. 2013;99(5):1173-81.
3. Буняева Е.С., Кириллова А.О., Назаренко Т.А., и др. Показания и эффективность технологии получения незрелых ооцит-кумулюсных комплексов из ткани яичника с последующим их дозреванием in vitro. Акушерство и гинекология. 2022;6:75-82 [Buniaieva YeS, Kirillova AO, Nazarenko TA, et al. Pokazaniia i effektivnost' tekhnologii polucheniia nezrelykh ootsit-kumuliusnykh kompleksov iz tkani iaichnika s posleduiushchim ikh dozrevaniiem in vitro. Akusherstvo i ginekologiia. 2022;6:75-82 (in Russian)].
4. Yasmin E, Balachandren N, Davies MC, et al. British Fertility Society Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline. Hum Fertil. 2018;21(1):3-26.
5. Harada M, Osuga Y. Fertility preservation for female cancer patients. Japan Soc Clin Oncol. 2018;24(1):28-33.
6. Dolmans MM, Manavella DD. Recent advances in fertility preservation. J Obstet Gynaecol Res. 2019;45(2):266-79.
7. Wallace WH, Anderson EA, Irvine DS. Fertility preservation for young patients with cancer: Who is at risk and what can be offered? Lancet Oncol. 2005;6:209-18.
8. Kato K. Vitrification of embryos and oocytes for fertility preservation in cancer patients. Reprod Med Biol. 2016;15(4):227-33.
9. Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377:1657-65.
10. Hart RJ. Optimizing the opportunity for female fertility preservation in a limited time-frame for patients with cancer using in vitro maturation and ovarian tissue cryopreservation. Fertil Steril. 2019;111(2):258-9.
11. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-10
12. Dinas KD. Fertility Counseling and Preservation for Breast Cancer Patient. Adv Exp Med Biol. 2020;1252:181-7.
13. Creux H, Monnier P, Son WY, et al. Immature oocyte retrieval and in vitro oocyte maturation at different phases of the menstrual cycle in women with cancer who require urgent gonadotoxic treatment. Fertil Steril. 2017;107(1):198-204.
14. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052.
15. Gong X, Li H, Zhao Y. The Improvement and Clinical Application of Human Oocyte In Vitro Maturation (IVM). Reprod Sci. 2022;29(8):2127-35.
16. Hatırnaz Ş, Ata B, Hatırnaz ES, et al. Oocyte in vitro maturation: A sytematic review. Turk J Obstet Gynecol. 2018;15(2):112-5.
17. Pincus GB. Unfertilized human tubal ova. Anat Rec. 1937;69:163-9.
18. Rock J, Menkin MF. In vitro fertilization and cleavage of human ovarian eggs. Science. 1946;100:105-7.
19. De Roo C, Tilleman K. In Vitro Maturation of Oocytes Retrieved from Ovarian Tissue: Outcomes from Current Approaches and Future Perspectives. J Clin Med. 2021;10(20):4680.
20. De Vos M, Grynberg M, Tuong MH, et al. Perspectives on the development and future of oocyte IVM in clinical practice. J Assist Reprod Genet. 2021;38(6):1265-80.
21. Edwards RG. Maturation in vitro of human ovarian oocytes. Lancet. 1965;2:926-9.
22. Herta AC, Lolicato F, Smitz JEJ. In vitro follicle culture in the context of IVF. Reproduction. 2018;156:59-73.
23. Элленбоген А., Шалом-пац Е., Аншина М.Б., Смирнова А.А. Дозревание ооцитов in vitro. Показания, техника и результаты. Проблемы репродукции. 2015;1:32-40 [Ellenbogen A, Shalom-paz E, Anshina MB, Smirnova AA. In Vitro Matitration of oocytes. Indication, technique and results. Russian Journal of Human Reproduction. 2015;21(1):32-40. (in Russian)].
24. Plancha CE, Rodrigues P, Marques M, et al. The time is ripe for oocyte in vitro maturation. J Assist Reprod Genet. 2021;38:1281-3.
25. Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril. 2021;115(2):298-304.
26. Shirasawa H, Terad Y. In vitro maturation of human immature oocytes for fertility preservation and research material. Reprod Med Biol. 2017;16:258-67.
27. Son WY, Henderson S, Cohen Y, et al. Immature Oocyte for Fertility Preservation. Front Endocrinol (Lausanne). 2019;10:464.
28. Yang ZY, Chian RC. Development of in vitro maturation techniques for clinical applications. Fertil Steril. 2017;108(4):577-84.
29. Walls ML, Hart R. In Vitro Maturation. Best Pract Res Clin Obstet Gynaecol. 2018;53:60-72.
30. Junk SM, Yeap D. Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome. Fertil Steril. 2012;98(4):888-92.
31. Gilchrist R.B, Luciano AM, Richani D, et al. Oocyte maturation and quality: Role of cyclic nucleotides. Reproduction. 2016;152:143-57.
32. Sánchez F, Lolicato F, Romero S, et al. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod. 2017;32:2056-68.
33. Hourvitz A, Yerushalmi GM, Maman E, et al. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield. Reprod Biomed Online. 2015;31:497-505.
34. Creux H, Monnier P, Son WY, Buckett W. Thirteen years’ experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments. J Assist Reprod Genet. 2018;35:583-92
35. Shapira M, Raanani H, Meirow D, IVF for fertility preservation in breast cancer patients-efficacy and safety issues. J Assist Reprod Genet. 2015;32:1171-8.
36. Abir R, Ben-Aharon I, Garor R, et al. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in pediatric female cancer patients before and after cancer therapy. Hum Reprod. 2016;31:750-62.
37. Azem F, Hasson J, Ben-Yosef D, et al. Histologic evaluation of fresh human ovarian tissue before cryopreservation. Int J Gynecol Pathol. 2010;29:19-23.

________________________________________________

1. Nazarenko TA, Ashrafian LA, Dzhanashvili LG, Martirosyan YO. Retention of reproductive material in cancer patients as a sociomedical and organizational problem. P.A. Herzen Journal of Oncology. 2020;9(1):60-5 (in Russian).
2. Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril. 2013;99(5):1173-81.
3. Buniaieva YeS, Kirillova AO, Nazarenko TA, et al. Pokazaniia i effektivnost' tekhnologii polucheniia nezrelykh ootsit-kumuliusnykh kompleksov iz tkani iaichnika s posleduiushchim ikh dozrevaniiem in vitro. Akusherstvo i ginekologiia. 2022;6:75-82 (in Russian).
4. Yasmin E, Balachandren N, Davies MC, et al. British Fertility Society Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline. Hum Fertil. 2018;21(1):3-26.
5. Harada M, Osuga Y. Fertility preservation for female cancer patients. Japan Soc Clin Oncol. 2018;24(1):28-33.
6. Dolmans MM, Manavella DD. Recent advances in fertility preservation. J Obstet Gynaecol Res. 2019;45(2):266-79.
7. Wallace WH, Anderson EA, Irvine DS. Fertility preservation for young patients with cancer: Who is at risk and what can be offered? Lancet Oncol. 2005;6:209-18.
8. Kato K. Vitrification of embryos and oocytes for fertility preservation in cancer patients. Reprod Med Biol. 2016;15(4):227-33.
9. Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377:1657-65.
10. Hart RJ. Optimizing the opportunity for female fertility preservation in a limited time-frame for patients with cancer using in vitro maturation and ovarian tissue cryopreservation. Fertil Steril. 2019;111(2):258-9.
11. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-10
12. Dinas KD. Fertility Counseling and Preservation for Breast Cancer Patient. Adv Exp Med Biol. 2020;1252:181-7.
13. Creux H, Monnier P, Son WY, et al. Immature oocyte retrieval and in vitro oocyte maturation at different phases of the menstrual cycle in women with cancer who require urgent gonadotoxic treatment. Fertil Steril. 2017;107(1):198-204.
14. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052.
15. Gong X, Li H, Zhao Y. The Improvement and Clinical Application of Human Oocyte In Vitro Maturation (IVM). Reprod Sci. 2022;29(8):2127-35.
16. Hatırnaz Ş, Ata B, Hatırnaz ES, et al. Oocyte in vitro maturation: A sytematic review. Turk J Obstet Gynecol. 2018;15(2):112-5.
17. Pincus GB. Unfertilized human tubal ova. Anat Rec. 1937;69:163-9.
18. Rock J, Menkin MF. In vitro fertilization and cleavage of human ovarian eggs. Science. 1946;100:105-7.
19. De Roo C, Tilleman K. In Vitro Maturation of Oocytes Retrieved from Ovarian Tissue: Outcomes from Current Approaches and Future Perspectives. J Clin Med. 2021;10(20):4680.
20. De Vos M, Grynberg M, Tuong MH, et al. Perspectives on the development and future of oocyte IVM in clinical practice. J Assist Reprod Genet. 2021;38(6):1265-80.
21. Edwards RG. Maturation in vitro of human ovarian oocytes. Lancet. 1965;2:926-9.
22. Herta AC, Lolicato F, Smitz JEJ. In vitro follicle culture in the context of IVF. Reproduction. 2018;156:59-73.
23. Ellenbogen A, Shalom-paz E, Anshina MB, Smirnova AA. In Vitro Matitration of oocytes. Indication, technique and results. Russian Journal of Human Reproduction.
2015;21(1):32-40. (in Russian).
24. Plancha CE, Rodrigues P, Marques M, et al. The time is ripe for oocyte in vitro maturation. J Assist Reprod Genet. 2021;38:1281-3.
25. Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril. 2021;115(2):298-304.
26. Shirasawa H, Terad Y. In vitro maturation of human immature oocytes for fertility preservation and research material. Reprod Med Biol. 2017;16:258-67.
27. Son WY, Henderson S, Cohen Y, et al. Immature Oocyte for Fertility Preservation. Front Endocrinol (Lausanne). 2019;10:464.
28. Yang ZY, Chian RC. Development of in vitro maturation techniques for clinical applications. Fertil Steril. 2017;108(4):577-84.
29. Walls ML, Hart R. In Vitro Maturation. Best Pract Res Clin Obstet Gynaecol. 2018;53:60-72.
30. Junk SM, Yeap D. Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome. Fertil Steril. 2012;98(4):888-92.
31. Gilchrist R.B, Luciano AM, Richani D, et al. Oocyte maturation and quality: Role of cyclic nucleotides. Reproduction. 2016;152:143-57.
32. Sánchez F, Lolicato F, Romero S, et al. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod. 2017;32:2056-68.
33. Hourvitz A, Yerushalmi GM, Maman E, et al. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield. Reprod Biomed Online. 2015;31:497-505.
34. Creux H, Monnier P, Son WY, Buckett W. Thirteen years’ experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments. J Assist Reprod Genet. 2018;35:583-92
35. Shapira M, Raanani H, Meirow D, IVF for fertility preservation in breast cancer patients-efficacy and safety issues. J Assist Reprod Genet. 2015;32:1171-8.
36. Abir R, Ben-Aharon I, Garor R, et al. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in pediatric female cancer patients before and after cancer therapy. Hum Reprod. 2016;31:750-62.
37. Azem F, Hasson J, Ben-Yosef D, et al. Histologic evaluation of fresh human ovarian tissue before cryopreservation. Int J Gynecol Pathol. 2010;29:19-23.

Авторы

Ю.Э. Доброхотова¹, И.А. Лапина*¹, А.А. Малахова¹, Т.Г. Чирвон¹, В.В. Таранов¹, Ю.А. Сорокин², В.М. Гомзикова¹, А.А. Затеева¹, М.В. Твердикова², О.В. Кайкова³

¹ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
²АО ГК «МЕДСИ» Клинико-диагностический центр на Солянке, Москва, Россия;
³АО ГК «МЕДСИ» Клиническая больница №2 в Боткинском проезде, Москва, Россия
*doclapina@mail.ru

________________________________________________

Yulia E. Dobrokhotova¹, Irina A. Lapina*¹, Anastasiya A. Malakhova¹, Tatiana G. Chirvon¹, Vladislav V. Taranov¹, Yury A. Sorokin², Valeriia M. Gomzikova¹, Anastasia A. Zateeva¹, Maria V. Tverdikova², Olesya V. Kaykova³

¹Pirogov Russian National Research Medical University, Moscow, Russia;
²MEDSI Clinical Diagnostic Center on Solyanka, Moscow, Russia;
³MEDSI Clinical Hospital №2 in Botkinsky Proezd, Moscow, Russia
*doclapina@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.